Fresenius : MAbxience and Teva announce strategic global license agreement for biosimilar oncology treatment -April 04, 2024 at 08:43 am EDT

mAbxience, a Fresenius Kabi majority-owned group, and Teva Pharmaceuticals International have entered a licensing agreement for a biosimilar candidate currently in development for the treatment...

Related Keywords

Spain ,United States ,Argentina ,Fresenius Kabi ,Teva Pharmaceuticals International ,Markets ,